Novel biomarkers for risk of prostate cancer: Results from a case-control study

Li Yang, Nilesh W. Gaikwad, Jane Meza, Ercole L. Cavalieri, Paola Muti, Bruce Trock, Eleanor G. Rogan

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. Although the estrogens estrone and estradiol are recognized to play very important roles in the risk of developing prostate cancer (Pca), the molecular mechanism by which estrogens initiate and/or promote Pca is still unknown. Substantial evidence supports that specific metabolites of estrogens, catechol estrogen quinones, can react with DNA to form depurinating estrogen-DNA adducts. Apurinic sites derived from depurination of these adducts can induce mutations leading to cancer. Once released from DNA, depurinating estrogen-DNA adducts are shed from cells into the bloodstream and excreted in urine. By analyzing profiles of estrogen metabolites, conjugates, and depurinating DNA adducts in urine from men with and without prostate cancer, potential biomarkers of Pca can be detected. The goal of this case-control study was to detect and identify potential biomarkers of Pca. METHODS. Urine samples from fourteen cases, men diagnosed with Pca, and 125 controls, men who had not been diagnosed with Pca, were partially purified by solid phase extraction and analyzed by ultraperformance liquid chromatography/tandem mass spectrometry. The urinary levels of androgens, estrogens, estrogen metabolites, conjugates and depurinating DNA adducts were measured. RESULTS. The ratio of depurinating estrogen-DNA adducts to the sum of the corresponding estrogen metabolites and conjugates was significantly higher in cases (median: 57.34) compared to controls (median: 23.39) (P < 0.001). CONCLUSIONS. This study suggests that depurinating estrogen-DNA adducts could serve as potential biomarkers to predict risk of Pca. They also could be useful tools for early clinical diagnosis and development of suitable strategies to prevent Pca.

Original languageEnglish (US)
Pages (from-to)41-48
Number of pages8
JournalProstate
Volume69
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Case-Control Studies
Prostatic Neoplasms
Estrogens
Biomarkers
DNA Adducts
Urine
Catechol Estrogens
Quinones
Estrone
DNA
Solid Phase Extraction
Tumor Biomarkers
Tandem Mass Spectrometry
Liquid Chromatography
Androgens
Early Diagnosis
Estradiol
Mutation

Keywords

  • Biomarker
  • Depurinating estrogen-DNA adducts
  • Prostate cancer

ASJC Scopus subject areas

  • Urology
  • Oncology
  • Medicine(all)

Cite this

Yang, L., Gaikwad, N. W., Meza, J., Cavalieri, E. L., Muti, P., Trock, B., & Rogan, E. G. (2009). Novel biomarkers for risk of prostate cancer: Results from a case-control study. Prostate, 69(1), 41-48. https://doi.org/10.1002/pros.20850

Novel biomarkers for risk of prostate cancer : Results from a case-control study. / Yang, Li; Gaikwad, Nilesh W.; Meza, Jane; Cavalieri, Ercole L.; Muti, Paola; Trock, Bruce; Rogan, Eleanor G.

In: Prostate, Vol. 69, No. 1, 01.01.2009, p. 41-48.

Research output: Contribution to journalArticle

Yang, L, Gaikwad, NW, Meza, J, Cavalieri, EL, Muti, P, Trock, B & Rogan, EG 2009, 'Novel biomarkers for risk of prostate cancer: Results from a case-control study', Prostate, vol. 69, no. 1, pp. 41-48. https://doi.org/10.1002/pros.20850
Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B et al. Novel biomarkers for risk of prostate cancer: Results from a case-control study. Prostate. 2009 Jan 1;69(1):41-48. https://doi.org/10.1002/pros.20850
Yang, Li ; Gaikwad, Nilesh W. ; Meza, Jane ; Cavalieri, Ercole L. ; Muti, Paola ; Trock, Bruce ; Rogan, Eleanor G. / Novel biomarkers for risk of prostate cancer : Results from a case-control study. In: Prostate. 2009 ; Vol. 69, No. 1. pp. 41-48.
@article{83b83fca26d04c42ba73b68a6392f367,
title = "Novel biomarkers for risk of prostate cancer: Results from a case-control study",
abstract = "BACKGROUND. Although the estrogens estrone and estradiol are recognized to play very important roles in the risk of developing prostate cancer (Pca), the molecular mechanism by which estrogens initiate and/or promote Pca is still unknown. Substantial evidence supports that specific metabolites of estrogens, catechol estrogen quinones, can react with DNA to form depurinating estrogen-DNA adducts. Apurinic sites derived from depurination of these adducts can induce mutations leading to cancer. Once released from DNA, depurinating estrogen-DNA adducts are shed from cells into the bloodstream and excreted in urine. By analyzing profiles of estrogen metabolites, conjugates, and depurinating DNA adducts in urine from men with and without prostate cancer, potential biomarkers of Pca can be detected. The goal of this case-control study was to detect and identify potential biomarkers of Pca. METHODS. Urine samples from fourteen cases, men diagnosed with Pca, and 125 controls, men who had not been diagnosed with Pca, were partially purified by solid phase extraction and analyzed by ultraperformance liquid chromatography/tandem mass spectrometry. The urinary levels of androgens, estrogens, estrogen metabolites, conjugates and depurinating DNA adducts were measured. RESULTS. The ratio of depurinating estrogen-DNA adducts to the sum of the corresponding estrogen metabolites and conjugates was significantly higher in cases (median: 57.34) compared to controls (median: 23.39) (P < 0.001). CONCLUSIONS. This study suggests that depurinating estrogen-DNA adducts could serve as potential biomarkers to predict risk of Pca. They also could be useful tools for early clinical diagnosis and development of suitable strategies to prevent Pca.",
keywords = "Biomarker, Depurinating estrogen-DNA adducts, Prostate cancer",
author = "Li Yang and Gaikwad, {Nilesh W.} and Jane Meza and Cavalieri, {Ercole L.} and Paola Muti and Bruce Trock and Rogan, {Eleanor G.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1002/pros.20850",
language = "English (US)",
volume = "69",
pages = "41--48",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Novel biomarkers for risk of prostate cancer

T2 - Results from a case-control study

AU - Yang, Li

AU - Gaikwad, Nilesh W.

AU - Meza, Jane

AU - Cavalieri, Ercole L.

AU - Muti, Paola

AU - Trock, Bruce

AU - Rogan, Eleanor G.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - BACKGROUND. Although the estrogens estrone and estradiol are recognized to play very important roles in the risk of developing prostate cancer (Pca), the molecular mechanism by which estrogens initiate and/or promote Pca is still unknown. Substantial evidence supports that specific metabolites of estrogens, catechol estrogen quinones, can react with DNA to form depurinating estrogen-DNA adducts. Apurinic sites derived from depurination of these adducts can induce mutations leading to cancer. Once released from DNA, depurinating estrogen-DNA adducts are shed from cells into the bloodstream and excreted in urine. By analyzing profiles of estrogen metabolites, conjugates, and depurinating DNA adducts in urine from men with and without prostate cancer, potential biomarkers of Pca can be detected. The goal of this case-control study was to detect and identify potential biomarkers of Pca. METHODS. Urine samples from fourteen cases, men diagnosed with Pca, and 125 controls, men who had not been diagnosed with Pca, were partially purified by solid phase extraction and analyzed by ultraperformance liquid chromatography/tandem mass spectrometry. The urinary levels of androgens, estrogens, estrogen metabolites, conjugates and depurinating DNA adducts were measured. RESULTS. The ratio of depurinating estrogen-DNA adducts to the sum of the corresponding estrogen metabolites and conjugates was significantly higher in cases (median: 57.34) compared to controls (median: 23.39) (P < 0.001). CONCLUSIONS. This study suggests that depurinating estrogen-DNA adducts could serve as potential biomarkers to predict risk of Pca. They also could be useful tools for early clinical diagnosis and development of suitable strategies to prevent Pca.

AB - BACKGROUND. Although the estrogens estrone and estradiol are recognized to play very important roles in the risk of developing prostate cancer (Pca), the molecular mechanism by which estrogens initiate and/or promote Pca is still unknown. Substantial evidence supports that specific metabolites of estrogens, catechol estrogen quinones, can react with DNA to form depurinating estrogen-DNA adducts. Apurinic sites derived from depurination of these adducts can induce mutations leading to cancer. Once released from DNA, depurinating estrogen-DNA adducts are shed from cells into the bloodstream and excreted in urine. By analyzing profiles of estrogen metabolites, conjugates, and depurinating DNA adducts in urine from men with and without prostate cancer, potential biomarkers of Pca can be detected. The goal of this case-control study was to detect and identify potential biomarkers of Pca. METHODS. Urine samples from fourteen cases, men diagnosed with Pca, and 125 controls, men who had not been diagnosed with Pca, were partially purified by solid phase extraction and analyzed by ultraperformance liquid chromatography/tandem mass spectrometry. The urinary levels of androgens, estrogens, estrogen metabolites, conjugates and depurinating DNA adducts were measured. RESULTS. The ratio of depurinating estrogen-DNA adducts to the sum of the corresponding estrogen metabolites and conjugates was significantly higher in cases (median: 57.34) compared to controls (median: 23.39) (P < 0.001). CONCLUSIONS. This study suggests that depurinating estrogen-DNA adducts could serve as potential biomarkers to predict risk of Pca. They also could be useful tools for early clinical diagnosis and development of suitable strategies to prevent Pca.

KW - Biomarker

KW - Depurinating estrogen-DNA adducts

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=58149328544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149328544&partnerID=8YFLogxK

U2 - 10.1002/pros.20850

DO - 10.1002/pros.20850

M3 - Article

C2 - 18816637

AN - SCOPUS:58149328544

VL - 69

SP - 41

EP - 48

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -